nasm glp 1 GLP-1 Evidence-based Review Noom expands its GLP-1 range

Bottom line: Tirzepatide became available for diabetes in May 2022 and for weight loss in November 2023, offering a new dual-action approach to metabolic health

Annual or semi-annual basic metabolic panels are reasonable monitoring for patients on 100 mg or more

As glucagon-like peptide 1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, become increasingly central to diabetes care owing to their cardiometabolic benefits, there is growing interest in their potential to offer broader protection against neurological and cerebrovascular complications in this vulnerable population

Benefits : Increased Energy : Supports the bodys ability to utilize fat as energy, enhancing endurance and overall vitality